AstraZeneca PLC (AZN) — closed signal from May 20, 2026
Partial Published before the outcome was known, scored automatically when the window closed on August 18, 2026.
Predicted vs. what happened
What happened
Reached 31% of the predicted growth at its peak, without hitting the target.
The thesis — published May 20, 2026
AstraZeneca gives a defensive holding in health care with clear, company-specific regulatory wins. Recent U.S. approvals for label expansions and a new drug strengthen the near-term story and give concrete events to watch. The price is steady near short-term support, and low sensitivity to market swings helps offset riskier tech positions over the next 0-3 months.
Primary drivers
- Recent approvals improve near-term outlook and news flow
- Enhertu label expansion supports oncology revenue growth
- Lower sensitivity to market moves provides defensive balance
- Price action is steadier than higher-volatility technology stocks
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.